G lutamate is the primary excitatory neurotransmitter in the brain and binds both ligand-gated ion channels such as the N-methyl-D-aspartate receptor (NMDAR) and G protein-coupled metabotropic receptors (mGluRs). Hypofunction of the NMDAR (a hypoglutamatergic state) represents a major hypothetical mechanism explaining the etiology of schizophrenia [1] [2] [3] . This hypothesis is based on initial observations that non-competitive NMDAR antagonists induce a transient psychosis, disrupt affect and impair cognitive function in healthy humans, and can exacerbate preexisting symptoms in patients with schizophrenia 4, 5 . Furthermore, NMDAR-mediated signaling and GluN2A tyrosine phosphorylation is significantly reduced in postmortem brains from schizophrenia subjects 3 . The NMDAR pathway is associated with several candidate genes for schizophrenia, including neuregulin-1, dysbindin, disrupted-in-schizophrenia 1 and metabotropic glutamate receptor 3 (mGluR3) 6 ; thus, NMDAR-mediated signaling is proposed to act as a point of convergence for various candidate pathways in this disorder.
Accumulating evidence suggests that the group II family of mGluRs (mGlu 2 and mGlu 3 ; mGluR2/3) may represent an important target in the treatment of schizophrenia 7, 8 . In NMDAR hypofunction models of psychosis, agonists of mGluR2/3 reduce phencyclidine-and dizocilpine-induced locomotor behaviours [9] [10] [11] . A recent phase II clinical trial showed that LY 214 0023, an oral prodrug of the selective mGluR2/3 agonist LY 404039, was effective in treating both positive and negative symptoms of schizophrenia after only 4 weeks of treatment 8 . Furthermore, group II mGluRs are highly expressed in regions of the brain associated with schizophrenia such as the prefrontal cortex and hippocampus 12, 13 . Although there is ample evidence that mGluR2/3 agonists are effective in schizophrenia, the exact mechanisms for their antipsychotic effects are unclear.
Group II mGluRs are predominantly expressed on presynaptic terminals where they inhibit release of glutamate and GABA 14 . Activation of postsynaptic mGluR2/3 negatively modulates neuronal excitability and plasticity 15, 16 . Given that mGluR2/3 mainly act presynaptically to inhibit glutamate release, it seems counterintuitive that activation of these receptors would ameliorate the hypoglutamatergic state found in schizophrenia. Therefore we examined the effects of mGluR2/3 activation on NMDA-evoked currents in identified CA1 pyramidal neurons of the hippocampus, a brain region implicated in the pathophysiology of schizophrenia 17, 18 .
Results
We initially examined the effects of mGluR2/3 activation on NMDAR-mediated field EPSPs (fEPSP NMDA ) in the CA1 region. Application of the selective mGluR2/3 agonist LY 379268 (30 nM) did not affect the amplitude of fEPSP NMDA (Fig. 1a) ; however, there was an increase in the variance of the fEPSP NMDA response, suggesting that postsynaptic NMDAR function may be enhanced in spite of a reduction in presynaptic release of glutamate. To determine whether mGluR2/3 activation enhances postsynaptic NMDAR function, we examined the AMPA/NMDA ratio of excitatory postsynaptic currents (EPSCs) at Schaffer Collateral-CA1 synapses. Application of LY 379268 (30 nM) resulted in a significant decrease of AMPA/NMDA EPSC ratio (p,0.05, Fig. 1b) , suggesting an enhancement of postsynaptic NMDAR function. To more directly examine the effects of mGluR2/3 activation on NMDARs, we examined the actions of LY 379268 on acutely isolated CA1 pyramidal neurons.
We previously demonstrated that Gaq-and Gas-coupled receptors potentiate NMDAR currents in isolated CA1 neurons via activation Src kinase and PKA, respectively [19] [20] [21] [22] [23] . Given that mGluR2/3 couple to Gai/o and inhibit adenylyl cyclase activity 14 , we anticipated that these receptors would inhibit NMDAR-mediated currents. To examine the direct effects of group II mGluRs on NMDARs, we determined the actions of LY 379268 on acutely isolated CA1 pyramidal neurons. These isolated neurons have a population of both extrasynaptic and synaptic NMDARs. Surprisingly, application of LY 379268 (10 nM) to acutely isolated CA1 neurons potentiated NMDA-evoked currents, with a significant potentiation occurring after washout of LY 379268 (Fig. 2) . The concentration of LY 379268 employed was chosen based on the 50% percent inhibitory concentration (IC 50 ) value of LY 379268 to displace [ 3 H]LY341495, a group II selective antagonist radioligand, from native rat brain homogenates and recombinant human mGlu2 and mGlu3 receptor subtypes 24 . The LY 379268-induced enhancement of NMDARmediated currents was blocked by co-application of the selective mGluR2/3 antagonist LY 341 495 (10 nM) (Fig. 3) . Conversely, coapplication of the selective group I mGluR antagonist, MPEP hydrochloride, did not prevent the enhancement of NMDAR currents by LY 379268 (Fig. 3) . These results confirm that the LY 379268-mediated potentiation of NMDAR currents was indeed mediated by mGlu2/3 receptors. Given that PKA promotes Ca 21 permeation through NMDARs and increases the amplitude of NMDA-evoked currents 25 , it seems counterintuitive that inhibition of the PKA pathway via group II mGluRs would mediate the enhancement of NMDAR currents. Instead, we hypothesized that stimulation of group II mGluRs results in a promiscuous activation of Gaq with a subsequent activation of PKC and/or Src leading to an enhancement of NMDAR currents 19, 20, 22, 23 . To test this hypothesis, we employed the Src(40-58) peptide which mimics the unique domain of Src and prevents its interaction with the NADH dehydrogenase subunit 2 domain in the NMDAR complex 26 . Thus, Src(40-58) acts as an interfering peptide to prevent the regulation of NMDARs by endogenous Src 26 . Including Src (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) in the patch pipette prevented the enhancement of NMDAR currents by LY 379268 (Fig. 4a) . The LY 379268-induced enhancement of NMDAR currents was not, however, prevented by application of the PKC inhibitor, bisindolylmaleimide I (0.5 mM, data not shown) suggesting that Src might be activated by an alternative mechanism. Using an approach similar to Gingrich et al.
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, we synthesized the Fyn interfering peptide, Fyn (39-57) that corresponds to a region of the unique domain of Fyn. We previously showed that Fyn(39-57) selectively blocks the potentiation of NMDAR currents by recombinant Fyn kinase but not by recombinant Src kinase 23 . Application of Fyn(39-57) inside the patch pipette failed to prevent the enhancement of NMDAR currents by LY 379268 (Fig. 4a) indicating that LY 379268 enhances Src but not Fyn activity to regulate NMDARs. To confirm these electrophysiological findings, we determined the relative activation of Src versus Fyn in hippocampal slices treated with or without LY 379268 (30 nM). The mGluR2/3 agonist enhanced phosphorylation of Src at Y416 (Fig. 4b) , a site whose phosphorylation is required for activation this kinase 27 . The LY 379268-mediated increase in Src Y416 phosphorylation was prevented by co-application of the mGluR2/3 antagonist LY 341 495 (Fig. 4b) . In contrast, LY 379268 failed to enhance the tyrosine phosphorylation of the analogous activation site of Fyn kinase, Y420 (Fig. 4b) 
28
. These findings illustrate that Src, and not Fyn, regulates the mGluR2/3-mediated modulation of NMDAR currents in dissociated CA1 neurons.
We previously reported that several GPCRs acting via Gaq activate Src kinase to phosphorylate the GluN2A subunit of this receptor 22, 23 . In this regard, we employed applications of zinc (300 mM) to selectively inhibit responses to heteromeric NMDARs containing two GluN2A subunits 23, 29 . The enhancement of NMDAR currents by LY 379268 was absent when GluN2A subunits were blocked with Zn 21 (Fig. 5a ). In contrast, the mGluR2/3-mediated modulation of NMDARs was still observed in the presence of the selective GluN2B antagonist, Ro 25-6981 (500 nM) (Fig. 5a ). We also examined the potential phosphorylation of GluN2A and GluN2B subunits and found that applications of LY 379268 enhanced tyrosine phosphorylation of GluN2A but not GluN2B subunits (Fig. 5b) . Thus, activation of mGluR2/3 selectively potentiates GluN2A-containing NMDAR currents.
Gas-dependent receptors enhance PKA and target Fyn kinase activation to enhance phosphorylation of NMDARs 23 . Given that Fyn kinase was not activated by LY 379268 and that mGluR2/3 classically signal via inhibition of PKA, we initially confirmed that LY 379268 does indeed inhibit cAMP in treated hippocampal slices. Applications of LY 379268 reduced basal levels of cAMP in a concentration-dependent manner with an IC 50 of 10.932 nM (Fig. 6a) .
Src is strongly regulated in CA1 hippocampal neurons by C-terminal Src kinase (Csk), which phosphorylates Src on the C-terminal tyrosine Tyr527 and maintains it in an inactive conformation 30 . Furthermore, the tyrosine kinase activity of Csk is increased by PKA-mediated phosphorylation 31 , suggesting that a decrease in PKA activity might inhibit Csk and lead to a disinhibition of Src activity. To test this possibility, we first determined whether activation of mGluR2/3 inhibits Csk activity. Treatment of hippocampal membranes with LY379268 led to a significant reduction of Csk activity, as assessed by phosphorylation of Ser364 (Fig. 6b) . Furthermore, LY379268 treatment significantly reduced Csk-mediated phosphorylation of Src at its C-terminal regulatory tyrosine Y527 (Fig. 7a) . Decreased phosphorylation of Y527 on Src prevents the intramolecular interaction with the SH2 domain and leads to an open conformation of Src 32, 33 . Thus, activation of mGluR2/3 may activate Src through inhibition of its regulatory partner Csk. To determine whether inhibition of PKA may activate Src and occlude the effects of LY379268 on NMDAR currents, we applied a highly selective PKA inhibitor in the patch pipette and examined the modulation of NMDAR currents by LY 379268. Under this condition LY 379268 failed to enhance NMDAR currents (Fig. 7b) suggesting that Src is activated, at least in part, by a reduction in PKA activity.
Discussion
We have shown that activation of group II mGluRs enhances postsynaptic NMDAR function in spite of reducing excitatory transmission. Application of the selective mGluR2/3 agonist LY 379268 increases the ratio of NMDA-to-AMPA EPSCs at Schaffer Collateral-CA1 synapses and enhances NMDA-induced currents in acutely isolated CA1 pyramidal neurons. The enhancement of NMDA-evoked currents was mediated by mGluR2/3 as it was inhibited by the selective group II mGluR antagonist LY 341 495. The Src family kinase Src, and not Fyn, was required for this potentiation as it was blocked by the selective Src-interfering peptide, Src(40-58), but not by the comparable Fyn interfering peptide, Fyn(39-57). Furthermore, LY 379268 increased the activity of Src kinase (increased phosphorylation of Tyr-416) but not that of Fyn (phosphorylation of Tyr-420 unchanged), leading to a selective tyrosine phosphorylation of GluN2A-versus GluN2B-containing NMDARs. Unlike Gaq-dependent signaling, the potentiation by LY 379268 was insensitive to a blocker of PKC and was occluded by an inhibitor of PKA. This suggests that the mechanism of Src activation by LY 379268 differs substantially from Gaq-coupled receptors which signal via sequential activation of PKC, Pyk2 and Src 20, 22, 34 . We provide evidence that group II mGluRs activate Src by inhibition of PKA and Csk activities. Activation of the cAMP-PKA pathway has previously been shown to down regulate Src kinase activity in a Csk-dependent manner 31, 35 . Activation of mGluR2/3 couples to the inhibition of PKA and decreases phosphorylation of Ser364 on Csk, thereby inhibiting Csk activity. This in turn reduces the ability of Csk to phosphorylate the regulatory Y527 on Src and promotes an active conformation of Src. However, we cannot rule out the potential role of activation of an unidentified tyrosine phosphatase, which would also reduce phosphorylation of Src at Tyr527. Src kinase activity can also be directly stimulated by Gai/o 36 . Activated Gai has been shown to interact directly with the catalytic domain of Src, thus changing the conformation of c-Src and allowing increased accessibility of the active site to substrates. Activation of Src by Gai-protein-coupled receptors has also shown to mediate Rasdependent activation of mitogen-activated protein kinases (MAPKs) in various cell types 37, 38 . Stimulation of the Gai-coupled a-2 adrenergic receptor leads to liberation of Gßc subunits and phospholipase C activation 37 . The resulting increase in intracellular Ca 21 activates calmodulin and Pyk2, which then activates c-src. Whether or not mGluR2/3 activates such a signaling pathway in parallel with an inhibition of PKA and Csk activities to up regulate Src kinase activity is unknown.
Agonists of group II mGluRs have opposing actions on pre-and post-synaptic sites: decreasing glutamate release presynaptically 14 and potentiating NMDAR function postsynaptically (our present findings). Thus, the relative contributions of pre-to post-synaptic effects of mGluR2/3 agonist in vivo could be complicated. One possibility is that reduced glutamate release will prevent the activation of extrasynaptic NMDARs and preferentially activate subsets of synaptic NMDARs. The NMDAR appears to be an important postsynaptic target for mGluR2/3 in the hippocampus. Activation of mGluR2/3 is also reported to decrease the AMPA-component of EPSPs, consistent with a reduction in presynaptic glutamate release 39, 40 . We have shown that mGluR2/3 activation decreases the ratio of AMPA-to-NMDA EPSCs, suggesting that LY 379268 increases the relative contribution of NMDARs to AMPARs in the synapse. The paradoxical effects of mGluR2/3 agonists on presynaptic glutamate release and postsynaptic NMDAR function can also be explained by the activation of extrasynaptic tonic NMDAR conductances. Ambient glutamate release from non-synaptic sources, such as glial cells, induces a tonic NMDA current primarily mediated by extrasynaptic NMDARs 41 . Given that acutely isolated neurons from the CA1 are heavily enriched in extrasynaptic NMDARs, we propose that LY 379268 may target these extrasynaptic NMDAR currents independently of vesicular glutamate release.
Several lines of evidence suggest that hypofunction of NMDARs underlies the pathophysiology of schizophrenia. Administration of dissociative anesthetics such as phencyclidine and ketamine to healthy volunteers produces behaviours similar to the positive, negative and cognitive symptoms of schizophrenia 1, 4 . Analysis of postmortem hippocampal tissue from schizophrenic patients reveals a decrease in GluN1 mRNA 42 . Candidate schizophrenia genes such as neuregulin 1 have been shown to promote rapid internalization of NMDARs from the cell surface and reduce whole-cell NMDAR currents 43 . In postmortem brains of schizophrenia subjects, enhanced ErbB4 signaling by neuregulin 1 mediates a suppression of GluN2A tyrosine phosphorylation, which promotes NMDAR internalization and decreases NMDAR signaling 3 . Thus, enhancing GluN2A-containing NMDAR function with group II mGluRs may counteract the effects of neuregulin 1 in these individuals and help stabilize NMDARs to the cell surface.
A recent study suggested that dysregulated Src activity mediates NMDAR hypofunction in schizophrenia induced by neuregulin-1-ErbB4 signaling, a candidate schizophrenia pathway 44 . Activation of neuregulin 1-ErbB4 signaling prevented the Src-induced potentiation of NMDAR-mediated synaptic currents in mouse prefrontal cortex and hippocampus. Thus, normalizing Src-mediated enhancement of NMDARs via activation of group II metabotropic glutamate receptors could represent a therapeutic avenue in the treatment of schizophrenia. The antipsychotic agent clozapine has also been shown to signal through Src kinase to potentiate NMDAR currents in the nucleus accumbens 45 . Thus, upregulation of Src activity may represent an important mechanism underlying the ability of these agents to relieve both positive and negative symptoms of schizophrenia.
Stimulation of group II mGluRs increases the function of postsynaptic NMDARs in hippocampal CA1 neurons via inhibition of PKA and activation of Src kinase. We propose that inhibition of the cAMP-PKA pathway decreases the activity of Csk, thereby decreasing the phosphorylation of its substrate Src at Tyr527. Reduced phosphorylation of Src at Tyr527 prevents the intramolecular interaction with the SH2 domain and leads to an active conformation of Src. However, we cannot rule out the potential role of activation of an unidentified tyrosine phosphatase, which might also reduce phosphorylation of Src at Tyr527. Up until now, the antipsychotic effects of group II mGluR agonists have been attributed to a decrease in presynaptic glutamate release. Given that schizophrenia is characterized by a hypoglutamatergic state, we propose that enhancing postsynaptic NMDAR function may be more relevant in restoring a balance of glutamatergic signaling in this disease. One candidate schizophrenia pathway leading to hypofunction of NMDARs implicates aberrant Src activity. Thus, we speculate that enhancing Src activity through group II mGluRs may represent one of the mechanisms for the antipsychotic effects of mGluR2/3 agonists.
Methods
Hippocampal slice preparation. Transverse hippocampal slices were prepared from 2-to 3-week old Wistar rats. Following anaesthetization of the animal, the brain was LY alone, 135 6 2%). LY 379268 (10 nM) was co-applied with NMDA/glycine solutions using the multi-barreled perfusion system. Fyn(39-57), 25 ng/ ml, and Src(40-58), 25 ng/ml, were included inside the patch pipette. Peak currents were averaged for 5 min prior to application of LY 379268 and were compared with currents averaged for values between 20 and 25 minutes. *Indicates P,0.01, one-way ANOVA. B) LY 379268 (30 nM) treatment increases the phosphorylation of Src(pSrcY416) but not Fyn (pFynY420). The enhanced Src phosphorylation was prevented by pre-treatment with the mGluR2/3 antagonist LY 341495 (30 nM). Below, summary of immunoblot analysis shows the averaged relative density of pSrcY416 and pFynY420 for each condition (n54). *Indicates P,0.05, Student's t-test.
www.nature.com/scientificreports SCIENTIFIC REPORTS | 3 : 926 | DOI: 10.1038/srep00926decapitated and quickly removed and placed in ice-cold oxygenated (95% O 2 , 5% CO 2 ) artificial cerebrospinal fluid (ACSF) containing (in mM): 124 NaCl, 3 KCl, 1.3 MgCl 2 -6H 2 O, 2.6 CaCl 2 , 1.25 NaH 2 PO 4 -H 2 O, 26 NaHCO 3 , 10 glucose with an osmolarity between 300-310 mOsm. Coronal hippocampal slices 300 mm thick were prepared using a vibratome (VT100E, Leica). Slices were allowed to recover for at least 1 hour in oxygenated ACSF until needed.
Field excitatory postsynaptic potentials (fEPSP) recording from Schaffer collateral-CA1 synapses. fEPSP NMDA were evoked every 30 s (0.033 Hz) by electrical stimulation (100 ms duration) delivered to the Schaffer-collateral pathway using a concentric bipolar stimulating electrode (25 mm exposed tip) and recorded using glass microelectrodes (3-5 MV, filled with ACSF) positioned in the stratum radiatum of the CA1 area, when bicuculline methiodide (10 mM) and CNQX (20 mM) were present. The input-output relationship and paired-pulse ratio was determined in each slice by varying the stimulus intensity (50-200 mA) and recording the corresponding fEPSP. The stimuli intensity was made as that to evoke 30-50% of the maximal fEPSP NMDA . After a 20min stable recording as baseline, LY379268 (30 nM) was bath applied. Signals were amplified (Axoclamp 700B, Molecular Devices, Sunnyvale CA, USA), recorded digitally (Digidata 1440A) and analyzed offline using Clampfit 10.
Whole-cell patch clamp recordings from hippocampal slices. A single slice was transferred to a recording chamber continually superfused with oxygenated ACSF (2 ml/min) composed of the following (in mM): 124 NaCl, 3 KCl, 1.25 NaH 2 PO4, 1.3 MgCl 2 , 2.6 CaCl 2 , 26 NaHCO 3 , 10 glucose, and 0.01 bicuculline methiodide (saturated with 95% O 2 -5%CO 2 at 31-33uC). Recording electrodes (4-6 MV) were filled with internal solution containing (in mM): Cs-gluconate 132.5, CsCl 17.5, HEPES 10, EGTA 0.2, Mg-ATP 2 and GTP 0.3 (pH 7.25, 290 mOsm). Visual patch recordings of CA1 pyramidal neurons were performed using whole-cell configuration with holding potential at 260 mV. Synaptic responses were evoked with a concentric bipolar tungsten electrode located about 50 mm from the cell body layer in CA1 when the neuron was held at 270 mV and 140 mV, respectively. The AMPAR and NMDAR-mediated EPSC was measured at the peak and 20 ms after the start of stimulus artifact at 270 mV and 140 mV respectively, as previously described 46 . Signals were amplified using Multiclamp 700B, sampled at 5 kHz, and analyzed with Clampfit 10 software (Axon Instruments, Foster City, CA).
Cell isolation and whole-cell recordings. CA1 neurons were isolated from the hippocampus of postnatal rats (Wistar, 14-22 days) using previously described procedures 47 . To control for variation in response, recordings from control and drugtreated cells were conducted on the same day. The extracellular solution was composed of the following (in mM): 140 NaCl, 1.3 CaCl 2 , 5 KCl, 25 HEPES, 20 glucose and 0.0005 tetrodotoxin, pH 7.4 (osmolality between 305 and 310 mOsm). Recording electrodes with resistances of 3-5 MV were constructed from borosilicate glass (1.5 mM diameter; World Precision Instruments, Sarasota, FL) using a two-stage puller (PP83; Narashige, Tokyo, Japan). Electrodes were filled with intracellular solution composed of the following (in mM): 140 CsF, 11 EGTA, 1 CaCl 2 , 2 MgCl 2 , 10 HEPES, 2 tetraethylammonium, and 2K2ATP, pH 7.2-7.3 (osmolality between 290 and 300 mOsm). Where indicated, some drugs were included inside the patch pipette. Recordings were performed at room temperature (20-22uC) . After formation of the whole-cell configuration, the neurons were voltage clamped at 260 mV and lifted into a stream of solution supplied by a computer-controlled, multi-barreled perfusion system (SF-77 B, Warner Instrument Corporation). The exchange time for solutions was ,30-50 ms. To monitor access resistance, a voltage step of 210 mV was made before each application of NMDA. If series resistance was increased to .20 MV, the cell was discarded. Currents were recorded using AxoPatch 1D amplifier. Data were filtered at 2 kHz and digitized at 10 kHz using Clampex software. cAMP assay. Hippocampal slices were prepared from Wistar rats (2-3 week old) and incubated in ACSF saturated with 95% O 2 and 5% CO 2 for at least 1 h at room temperature. Hippocampal tissue was then treated with 30 nM LY 379268 or vehicle control for 20 minutes. The treated tissue was then washed with cold ACSF 3 times and frozen immediately in liquid nitrogen. Equal amounts of frozen tissue were homogenized in 10 volumes of 0.1 M HCl and the debris was centrifuged at 10, 000 rpm for 10 min at 4uC (Eppendorf Centrifuge 5415R). Cyclic AMP levels were determined using the cAMP Immunoassay kit (Assay Designs, Ann Arbor, Michigan, USA). In order to increase the sensitivity of cAMP measurement, the supernatant was diluted 10-fold with distilled water. For the assay, 100 ml of the diluted sample, 50 ml of blue conjugate and 50 ml of yellow antibody were each added to the bottom of appropriate wells sequentially, and the reaction was incubated for 2 hours on a plate shaker at room temperature. The standards were prepared following the protocol supplied by the company. After incubation, the wells were emptied and washed 3 times with 400 ml of wash buffer. 200 ml of substrate solution was then added into each well. The reaction was stopped by adding 50 ml of stop solution and incubated at room temperature for 1 hour without shaking. The optical density of each well was then determined with a microplate reader set to 405 nm. Statistics. All population data are expressed as mean 6 SD. Student's t-test was used to compare between two groups and one-way ANOVA with Tukey's post-hoc comparison was used to compare multiple groups.
